Abstract:685 Background: mUC often carries a poor prognosis, and a subset of patients (pts) progresses within weeks of starting frontline therapy. While clinicopathologic predictors such as the Bellmunt score have been proposed, predicting this high-risk subset is challenging. Next generation sequencing (NGS) may identify predictive biomarkers for pts with rapid tumor progression, but the predictive value of variant allele frequency (VAF) of genomic alterations is uncertain. Methods: An IRB-approved, HIPAA-compliant single institution retrospective database of pts diagnosed with mUC from 1/2013-3/2023 with somatic NGS and were treated with standard of care therapy was generated. Baseline demographics, clinicopathologic features, and NGS results including pathogenic/likely pathogenic mutations, fusions, copy number alterations, and VAF were extracted from the electronic health record. Progression-free survival (PFS) was calculated from the start of frontline (1L) treatment until radiographic/pathologic progression or death from cancer, whichever came first. PFS 180 days was considered sustained response (SR). Statistical analysis included chi-square and student paired t-test. Results: 260 pts with mUC were identified, and 86 pts had available NGS data. Clinical data cutoff was 9/2023. NGS results used in this analysis were based on the primary tumor (64.0%), distant metastasis (27.9%), or blood (5.8%). Comparing the RP cohort (n=29) vs SR cohort (n=40), there were no significant differences for median age at mUC onset (68 v 68 yrs), proportion of female pts (34 v 28%), Black ancestry (14 v 5%), or smoking history (66 v 68%). Notable variant histologies included squamous cell (28 v 10%, p=0.051) and small cell (0 v 10%, p=NA). 1L treatment involved cisplatin (38 v 43%), carboplatin (17 v 35%), oxaliplatin (0 v 2.5%), or immune checkpoint inhibitor monotherapy (45 v 20%). At mUC, RP cohort pts had more liver metastases (31 v 10%, p=0.027). Median TMB was 10.5 (n=17) vs 6.6 mut/Mb (n=27). No significant difference between RP and SR was observed in the incidence of alterations in TP53 (52 v 58%), TERT promoter (50 v 71%), PIK3CA (41 v 28%), ARID1A (27 v 23%), and KMT2D (14 v 26%). Pts in the RP cohort were significantly more likely to have lower VAF for TP53 ( p=0.006) and KMT2D ( p=0.028). Amongst 1L platinum-treated pts, low TP53 VAF remained significantly associated with the RP cohort ( p=0.010) and KMT2D VAF nearly significant ( p=0.077). Conclusions: Pts with mUC who rapidly progressed on frontline therapy had a significantly higher liver involvement at mUC diagnosis, a trend toward squamous histology, and a significantly lower VAF for TP53 and KMT2D alterations. VAF is a potential predictive biomarker that should be further investigated. We plan to validate these findings in larger cohorts.

Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies

Single-center analysis on a real-world cohort of patients with metastatic urothelial carcinoma studied by NGS: Molecular landscape and efficacy of targeted therapies.

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer

The genomic and transcriptomic landscape of metastastic urothelial cancer

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC).

Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma

Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 San Raffaele Retreat panel

Comprehensive Genomic Landscape in Chinese Patients with Urothelial Carcinoma.

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain

Novel Use of Ctdna to Identify Muscle-Invasive and Non-Organ-confined Upper Tract Urothelial Carcinoma.

Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience.

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

The evolving treatment landscape of metastatic urothelial cancer

Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis

The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).